Post-hoc analysis of Deucravacitinib (TYK2i) for tx of PsA showed similar efficacy in pts with and without background csDMARD use.
⭐️>60% w/ background csDMARD use, majority of which was MTX
⭐️no difference in AE
#ACR21
Abs#1352
@RheumNow
https://t.co/nIJT7rNkJP https://t.co/bq0x1Ywguo
Links:
Deucravacitinib Efficacy in Psoriatic Arthritis (PsA) by Baseline DMARD Use: Ex…
https://bit.ly/3CVIGDr
08-11-2021